浙江震元(000705.SZ):生物定向合成組氨酸、左旋多巴等系列產品及高端原料藥上虞產業化基地項目入選2021年浙江省重大產業項目(第一批)名單
格隆匯8月31日丨浙江震元(000705.SZ)公佈,日前,公司收到《浙江省發展改革委、浙江省自然資源廳關於印發 2021年浙江省重大產業項目(第一批)名單的通知》(浙發改投資〔2021〕321 號),浙江震元製藥有限公司生物定向合成組氨酸、左旋多巴等系列產品及高端原料藥上虞產業化基地項目入選2021年浙江省重大產業項目(第一批)名單中的示範性重大產業項目(生命健康類)。
近年來,公司持續加強與中科院系研究所等高端科研院所的深度合作,在生物定向合成等領域積極開展戰略合作,目前部分產品已完成小試、中試。此次項目建設有利於發揮公司在生物定向合成等領域的技術優勢和工業化生產經驗,加快推進公司在大健康領域新產品的生產佈局,推動公司轉型升級。
此次項目有利於鞏固與提升現有藥品和大健康產品生產能力,促進產品銷售、盈利能力提升,促進公司業務的發展和產業核心競爭力的增強,從而提升公司的市場競爭力和市場佔有率,進一步提高公司的品牌影響力和綜合實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.